Paper41409286
The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy.
Wang Z and 2 others. Front Immunol, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy. Papers, record 41409286. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41409286
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunotherapy, Adoptive | Major topic |
| Breast Neoplasms | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| T-Lymphocytes | Major topic |
| Humans | |
| Female | |
| Tumor Microenvironment | |
| Animals | |
| Antigens, Neoplasm | |
| Receptors, Antigen, T-Cell | |
| Coping Skills |
Source PubMed
References134
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34378338 | Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy. | Small | 2021 | https://conductscience.org/library/papers/34378338 | PubMed |
| 2 | 25849134 | Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. | Nat Med | 2015 | https://conductscience.org/library/papers/25849134 | PubMed |
| 3 | 39213364 | Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. | Sci Adv | 2024 | https://conductscience.org/library/papers/39213364 | PubMed |
| 4 | 34343496 | CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. | Cell | 2021 | https://conductscience.org/library/papers/34343496 | PubMed |
| 5 | 40102282 | Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies. | Med Oncol | 2025 | https://conductscience.org/library/papers/40102282 | PubMed |
| 6 | 33010818 | Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. | Mol Ther | 2021 | https://conductscience.org/library/papers/33010818 | PubMed |
| 7 | 40715608 | Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells. | Med Oncol | 2025 | https://conductscience.org/library/papers/40715608 | PubMed |
| 8 | 40072049 | Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy. | Cells | 2025 | https://conductscience.org/library/papers/40072049 | PubMed |
| 9 | 28223273 | PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28223273 | PubMed |
| 10 | 39511890 | Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis. | Mol Ther | 2025 | https://conductscience.org/library/papers/39511890 | PubMed |
| 11 | 27526682 | Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. | J Hematol Oncol | 2016 | https://conductscience.org/library/papers/27526682 | PubMed |
| 12 | 40033418 | Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/40033418 | PubMed |
| 13 | 34048683 | CAR T-cell therapy for multiple myeloma: state of the art and prospects. | Lancet Haematol | 2021 | https://conductscience.org/library/papers/34048683 | PubMed |
| 14 | 40460374 | Spatiotemporal dynamics of tumor-CAR T-cell interaction following local administration in solid cancers. | PLoS Comput Biol | 2025 | https://conductscience.org/library/papers/40460374 | PubMed |
| 15 | 30404198 | Receptor Tyrosine Kinase-Targeted Cancer Therapy. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30404198 | PubMed |
| 16 | 37418008 | CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer. | Cancer Immunol Immunother | 2023 | https://conductscience.org/library/papers/37418008 | PubMed |
| 17 | 40514065 | Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40514065 | PubMed |
| 18 | 33382402 | STING agonist promotes CAR T cell trafficking and persistence in breast cancer. | J Exp Med | 2021 | https://conductscience.org/library/papers/33382402 | PubMed |
| 19 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 20 | 37377890 | Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. | Cancer Res Commun | 2023 | https://conductscience.org/library/papers/37377890 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42769774 | Metastatic Triple Negative Breast Cancer: Navigating a Rapidly Evolving Therapeutic Landscape. | Oncol Res | 2026 | https://conductscience.org/library/papers/42769774 | PubMed |
| 42527931 | Harnessing immunity against breast cancer: from checkpoints to cell therapies. | J Transl Med | 2026 | https://conductscience.org/library/papers/42527931 | PubMed |
| 42224282 | Multi-omics and pan-cancer analysis revealed common molecular signatures to disclose multitargeted anticancer agents through network pharmacology approach. | PLoS One | 2026 | https://conductscience.org/library/papers/42224282 | PubMed |
| 42214174 | Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42214174 | PubMed |
| 41976388 | Human-Centric Modeling in Metastatic Breast Cancer: Organoids, Organ-on-Chip Systems, and New Approach Methodologies in the Post-FDA Modernization Act 2.0 Era. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41976388 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41409286
GET https://conductscience.org/api/papers/v1/41409286/references?page=2